G20210A Prothrombin gene mutation in two siblings with cerebral venous thrombosis

Neurology ◽  
1998 ◽  
Vol 51 (1) ◽  
pp. 316-317 ◽  
Author(s):  
G. Huberfeld ◽  
N. Kubis ◽  
G. Lot ◽  
L. Ripoll ◽  
P. Chaine ◽  
...  
2001 ◽  
Vol 120 (4) ◽  
pp. 1059-1060 ◽  
Author(s):  
Pasquale Madonna ◽  
Valentino de Stefano ◽  
Antonio Coppola ◽  
Anna Maria Cerbone ◽  
Giovanni di Minno

2005 ◽  
Vol 93 (06) ◽  
pp. 1021-1026 ◽  
Author(s):  
Martin den Heijer ◽  
Johannes Cruysberg ◽  
Hub Wollersheim ◽  
Sebastian Bredie ◽  
Mirian Janssen

SummaryPrevious studies have shown an increased risk of retinal vein occlusion (RVO) in patients with hypertension, hypercholesterolemia and diabetes mellitus. Literature on the association between thrombophilic factors and RVO consists of small studies and case reports. The objective was to determine the relationship between thrombophilic risk factors and RVO. Thrombophilic risk factors analyzed were hyperhomocysteinemia, MTHFR gene mutation, factor V Leiden mutation, protein C and S deficiency, antithrombin deficiency, prothrombin gene mutation, anticardiolipin antibodies and lupus anticoagulant. For all currently known thrombophilic risk factors odds ratios for RVO were calculated as estimates of relative risk. The odds ratios were 8.9 (95% CI 5.7 –13.7) for hyperhomocysteinemia, 3.9 (95% CI 2.3 – 6.7) for anticardiolipin antibodies, 1.2 (95% CI 0.9 –1.6) for MTHFR, 1.5 (95% CI 1.0 – 2.2) for factor V Leiden mutation and 1.6 (95% CI 0.8 – 3.2) for prothrombin gene mutation. In conclusion, regarding thrombophilic risk factors and RVO there is only evidence for an association with hyperhomocysteinemia and anticardiolipin antibodies, factors that are known as risk factors for venous thrombosis as well as for arterial vascular disease. The minor effect of factor V Leiden mutation and the protrombin gene mutation (risk factors for venous thrombosis only) suggests that atherosclerosis might be an important factor in the development of CRVO.


2000 ◽  
Vol 118 (4) ◽  
pp. A354-A355
Author(s):  
Terence Wong ◽  
Jo Nightingale ◽  
Azhar Ansari ◽  
Jeremey Sanderson ◽  
Mark Winter ◽  
...  

1997 ◽  
Vol 17 (11) ◽  
pp. 2875-2879 ◽  
Author(s):  
Rajesh K. Kapur ◽  
Lisa A. Mills ◽  
Silvia G. Spitzer ◽  
Mae B. Hultin

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1050-1050
Author(s):  
Andrea Gerhardt ◽  
Tamme W. Goecke ◽  
Matthias W. Beckmann ◽  
Rudiger E. Scharf ◽  
Rainer B. Zotz

Abstract Obstetrical complications such as severe preeclampsia and HELLP syndrome are associated with abnormal placental vasculature and inadequate placental maternal-fetal circulation. Hereditary risk determinants of venous thrombosis have been reported to be associated with these obstetrical complications.The magnitude of the association between thrombophilia and the obstetrical complications varies in the published studies, according to type of obstetrical complication and type of thrombophilia. No data exist so far whether these risk determinants are related to premature onset of severe preeclampsia. We used a case-control design in 99 women with severe preeclampsia (blood pressure higher than 160/100 mm Hg; urinary protein excretion greater than 5 g per day, platelet count of less than 100.000/μl; combination of hemolysis, high serum aminotransferase concentration, and platelet count below 100.000/μl; or eclampsia) in previous pregnancies and 277 normal women to assess hereditary risk factors of venous thrombosis as risk determinants for severe preeclampsia. Moreover, a case-only design was used to assess these risk factors as risk determinants for premature severe preeclampsia. We determined the genetic risk markers factor V Leiden G1691A (FVL), the G20210A prothrombin gene mutation, the methylenetetrahydrofolate reductase polymorphism (MTHFR C677T), and the PAI A844G polymorphism. None of the women had a combined or homozygous defect of the FVL or the G20210A prothrombin gene mutation. Women with antiphospholipid syndrome were excluded. None of the women had a deficiency of antithrombin, protein C, or protein S. Using the case-control design, there was no significant risk association of the hereditary risk factors with severe preeclampsia (FVL p=0.680, prothrombin mutation p=0.479, MTHFR 677TT genotype p=0.565, PAI 844GG genotype p=0.641). In the case-only design, the onset of severe preeclampsia was significantly earlier in women with the G20210A prothrombin gene mutation (24.5 weeks vs. 30.5 weeks, p=0.04) and in women with the PAI 844GG genotype (27.2 weeks vs. 30.7, p=0.025). No such significant difference was observed in carriers of the FVL or the MTHFR 677TT genotype. Hereditary risk factors for venous thrombosis are not risk determinants for severe preeclampsia. However, women who are carriers of the G20210A prothrombin gene mutation and the PAI 844GG genotype are at risk for premature onset of severe preeclampsia. Based on our results it appears that these risk factors do not induce the pathomechanism but modulate the course of preeclampsia.


2009 ◽  
Vol 3 (1) ◽  
pp. 147-151 ◽  
Author(s):  
F.M. Attia ◽  
D.P. Mikhailidis ◽  
S.A. Reffat

Aim: The pathogenesis of deep venous thrombosis (DVT) involves an interaction between hereditary and acquired factors. Prothrombin gene mutation is one of the hereditary risk factors. We evaluated the frequency of the prothrombin gene mutation in patients with DVT and its relation to oral warfarin anticoagulant therapy response.Methods: Prothrombin gene mutation was looked for in 40 DVT patients with poor response to warfarin. The results were compared with 40 DVT patients with a normal response to warfarin and 30 healthy blood donors. Blood samples were also assessed for protein C, protein S, anti-thrombin III and anticardiolipin antibodies (ACA) levels.Results: Prothrombin gene mutation was found in normal and poor DVT responders (6/40 and 13/40, respectively; p = NS) as well as in healthy controls (1/30). Patients with recurrent DVT or a family history of DVT were significantly (p<0.0001) more likely to have the prothrombin mutation than other DVT patients. Non prothrombin abnormalities (protein C, anti-thrombin III and ACA) were more common in poor responders than controls (p<0.0037) as were ACA (p<0.034).Conclusions: Prothrombin gene mutation is present in several DVT patients, especially those with recurrent DVT or a family history of DVT. This mutation may contribute to a poor response to warfarin.


Sign in / Sign up

Export Citation Format

Share Document